Amgen's Dazodalibep Hits Phase 3 Primary Endpoint in Sjogren's Disease

Amgen (AMGN) reported positive topline results Tuesday from its Phase 3 OASIZ 301 trial of dazodalibep in adults with Sjogren's disease and moderate-to-severe systemic disease activity, clearing the study's primary endpoint. The announcement, dated September 22, 2026, marks a late-stage win for the California-based biotech's immunology pipeline. Amgen did not disclose detailed efficacy figures or safety data in its initial release. Sjogren's disease is a chronic autoimmune disorder affecting the glands that produce tears and saliva. Few targeted therapies are approved for the condition, leaving a sizable unmet need that dazodalibep could address if it advances toward regulatory review. Amgen said it plans to present full results at a future medical meeting and to discuss next steps with regulators. The company's shares trade on Nasdaq under the ticker AMGN.